Acadia soars on pimavanserin update

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $5.13 (64%) to $13.10 on Thursday after announcing that FDA said existing data, including a single Phase III trial, were sufficient to support an NDA for pimavanserin to...